KOSDAQBiotech & Pharma104540

Corentec

₩4,460▼ 1.33%2026-11-18 close
Market Cap
₩59.8B
Turnover
₩100M
Volume
20K
Shares out.
13.4M
PER
12.8×
PBR
0.8×
EPS
₩379
Dividend Yield
0.00%

PER, EPS, PBR and BPS are calculated in-house from the last 4 quarters (2025Q4–2026Q3) · Dividend yield is based on ₩0 per share · Prices as of the 2026-11-18 close

01

Report overview

Profit Recovery and the US Knee Push Ahead

Corentec returned to profit in 2025 after a 2024 loss, but posted a parent-level net loss in Q3 2026, so US sales and knee-joint R&D results are the next checkpoints.

  1. 1

    Revenue reached KRW 100.4 billion in 2025, the largest year in 2022–2025, and the operating margin recovered to 9.1%.

  2. 2

    Q3 2026 operating profit was KRW 1.8 billion, down 50.3% year on year, and the company posted a parent net loss of KRW 707 million.

  3. 3

    Using proceeds from the Woosung Pharma stake sale, the company repaid borrowings, and its debt ratio fell from 92.8% at end-2025 to 77.0% in Q3 2026, per preliminary reports dated November 9, 2026.

  4. 4

    The US business accounts for about 20% of revenue, yet its US market share is about 0.2%, and the company frames US and knee-joint expansion as its medium-term task.

  5. 5

    The share price sits below book value, and parent-level net income over the last four quarters totals KRW 5.54 billion, with most of it from Q4 2025.

02

Business structure

Corentec, founded in May 2000, manufactures and sells artificial joints, centered on artificial hip joints and extending into artificial knee joints, shoulder joints and spinal fixation devices.

The company says it held the No. 1 share of the Korean artificial hip joint market in 2025 and is upgrading its knee-joint lineup on that clinical base. Overseas sales were KRW 29.1 billion in 2023, about 40% of total revenue (per a 2024 report).

Within overseas sales, the United States generated KRW 13.7 billion in 2023, and the company now says the US business accounts for about 20% of total revenue.

Outside the US, it signed a supply contract with Mexico's Biortotec worth about USD 10 million through 2027 and a supply deal with Russia's Labmedexpert running through 2028. In 2026 it sold its stake in Woosung Pharma, a non-core pharmaceutical unit, to refocus the business on artificial joints.

Its differentiation rests on a bone-cement-free fixation technology and an uncemented knee-joint pipeline. The company cites leadership in the Korean hip market, while it sees the US, where its market share is low, as the main room for growth. It also states that the US accounts for about 64% of the global joint replacement market.

03

Earnings trend

Quarterly revenue · Operating profit
RevenueOperating profit
Annual revenue · Operating profit
RevenueOperating profit
Quarterly results · Last 5 quarters
QuarterRevenueOperating profitOp. margin
2025Q3₩25.8B₩3.6B14.0%
2025Q4₩28.6B₩3.1B10.8%
2026Q1₩24.6B₩900M3.6%
2026Q2₩25.8B₩1.5B5.6%
2026Q3₩25.6B₩1.8B7.0%
Annual results
YearRevenueOperating profitNet income (parent)Op. marginROEDebt-to-equity
2022₩63.9B₩5.8B₩2.7B9.1%4.0%128.3%
2023₩92B₩7.1B₩5.1B7.7%7.0%117.3%
2024₩93.7B₩3.9B-₩1.3B4.2%−1.8%120.6%
2025₩100.4B₩9.1B₩7B9.1%8.9%92.8%

Consolidated basis (financial statements including subsidiaries) · Final figures from DART filings · Net income attributable to owners of the parent · Data as of 2026-11-09

04

Earnings analysis

Annual revenue went from KRW 63.9 billion in 2022 to KRW 92 billion in 2023 (up 44.0% year on year), KRW 93.7 billion in 2024 (up 1.8%) and KRW 100.4 billion in 2025 (up 7.2%), rising for three consecutive years from 2023 through 2025. Within 2022–2025, 2025 was the largest year and 2022 the smallest.

The company described 2023 as its record performance at the time, citing US sales growth and domestic artificial joint demand. Operating profit was KRW 5.85 billion in 2022, KRW 7.05 billion in 2023 (up 20.7%), KRW 3.89 billion in 2024 (down 44.8%) and KRW 9.12 billion in 2025 (up 134.3%).

The operating margin slid from 9.1% in 2022 to 7.7% in 2023 and 4.2% in 2024 before recovering to 9.1% in 2025. Parent-level net income turned from KRW 5.13 billion in 2023 to a net loss of KRW 1.32 billion in 2024, then returned to a profit of KRW 6.97 billion in 2025.

Net income including non-controlling interests followed the same path. Operating cash flow was KRW 10.6 billion in 2022 and KRW 2.63 billion in 2023, turned negative at -KRW 6.61 billion in 2024, then recovered to KRW 26.5 billion in 2025.

At end-2025, total equity was KRW 89.2 billion, of which KRW 78.4 billion belonged to parent shareholders, and total liabilities were KRW 82.8 billion. On a quarterly basis, operating profit moved from KRW 3.62 billion in Q3 2025 to KRW 3.09 billion in Q4 2025, then fell to KRW 886 million in Q1 2026, the low point.

It then rose to KRW 1.45 billion in Q2 2026 and KRW 1.8 billion in Q3 2026, an increase in two consecutive quarters, yet Q3 2026 was still down 50.3% year on year.

Parent-level net income was KRW 1.44 billion in Q3 2025, KRW 3.87 billion in Q4 2025, KRW 1.28 billion in Q1 2026 and KRW 1.1 billion in Q2 2026, before a parent net loss of KRW 707 million in Q3 2026.

Preliminary first-half 2026 results, announced July 24, 2026, showed revenue of KRW 50.37 billion (up 9.4%), with the company attributing flat operating profit to upfront costs for US product launch preparation and vendor diversification.

05

Industry analysis

Demand in the artificial joint market depends on hip and knee surgery volumes, and the company states that the US accounts for about 64% of the global joint replacement market. Within that structure, Corentec's overseas share of sales was about 40% in 2023, and the company now puts the US share at about 20% of revenue.

A US market share of about 0.2% signals room for expansion, but it also makes US distributor relationships and product approval timing key variables. The company moved its US branch to California to push into the West Coast.

Its product expansion targets include a spinal fixation device and a shoulder joint product for which FDA clearance has been obtained or is in progress.

In Korea, the company points to its hip-market leadership and a clinical track record, while domestic demand is generally described as moving with reimbursement and surgery volumes.

In the US, it competes head-on with large global orthopedic makers and is trying to differentiate with a bone-cement-free technology and uncemented knee implants. On costs, it hired a supply chain specialist with prior experience at Alcon and GE Healthcare to improve manufacturing and logistics. Its supply contracts in Mexico and Russia run through 2027 and 2028.

06

Outlook

The company expects its Q4 seasonal peak, when orthopedic surgeries and product shipments are typically busier, to lift results. It says Q3 operating profit already absorbed upfront R&D spending aimed at entering large global markets.

The company expects gradual operating margin gains once its US and knee-joint R&D results become visible and cost and process improvements take hold.

Its pipeline includes next-generation custom implants such as an uncemented knee joint, and the timing of any US FDA decisions will be confirmed when the company discloses them. Reports say the spinal fixation device has completed product approval and the shoulder joint product is under review.

On shareholder returns, the company has mentioned dividends and share buybacks, but no specific amounts or timing have been disclosed. On the balance sheet, repaying borrowings with proceeds from the Woosung Pharma stake sale lowered the debt ratio and, the company says, freed capacity for R&D.

The 2026 annual report, the next regular filing, will show Q4 revenue and operating profit, which will reveal how much the seasonal peak contributed. The same filing will show operating cash flow and year-end debt structure.

If R&D costs continue to be expensed at this level, the pace of margin recovery could be limited. With the US now about 20% of revenue, US sales performance is increasingly what drives the overall direction of results.

07

Valuation

PER
12.8×
PBR
0.8×
ROE
7.0%
EPS
₩379
BPS
₩6,334
Dividend per share
₩0

The share price currently sits below book value, with the price-to-book ratio under 1x. A market data service's figures from around 2021 showed the ratio above 3x, so the valuation structure has changed considerably since then. Reading the price-to-earnings ratio depends on which earnings base is used.

Parent-level net income over the last four quarters totals KRW 5.54 billion, and most of it came from Q4 2025 at KRW 3.87 billion. The Q3 2026 parent net loss has thinned the recent earnings base, so the multiple looks different depending on whether the full-year 2025 profit or the last four quarters is the reference.

The dividend yield is effectively negligible, and the company has referred to dividends and share buybacks as shareholder return tools. On the equity side, the parent-owned portion at end-2025 was KRW 78.4 billion, and the balance sheet improved as the debt ratio fell.

PER, EPS, PBR and BPS are all calculated in-house (the same method as Naver and Toss) · Dividend yield = cash dividend per share from DART filings (supplemented by KRX) ÷ current price · As of 2026-11-09

08

Bull factors

Domestic leadership and room in the US

The company says it held the No. 1 share of the Korean artificial hip joint market in 2025. The US business is about 20% of revenue, while the US market share is about 0.2%, which the company frames as room for growth. Because the US market is large, even a small gain in share could have a meaningful effect on revenue.

Balance sheet repair and profit recovery

Using proceeds from the Woosung Pharma stake sale, the company repaid borrowings, lowering its debt ratio from 92.8% at end-2025 to 77.0% in Q3 2026 per preliminary reports. Operating profit rose 134.3% to KRW 9.12 billion in 2025, and operating cash flow recovered to KRW 26.5 billion.

Operating profit rebound since Q2

Operating profit rose for two consecutive quarters, from KRW 886 million in Q1 2026 to KRW 1.45 billion in Q2 and KRW 1.8 billion in Q3. The company expects its Q4 seasonal peak to lift results. It also expects cost reduction and process improvements to produce gradual margin gains.

09

Bear factors

Q3 profit slowdown and renewed net loss

Q3 2026 operating profit of KRW 1.8 billion fell 50.3% year on year. The company posted a parent net loss of KRW 707 million, turning to a loss from a year earlier. Excluding the KRW 3.87 billion parent profit in Q4 2025, the other three quarters of the last four combined contributed little.

Upfront R&D spending

The company said Q3 2026 operating profit absorbed upfront R&D spending aimed at large global markets. It also said first-half 2026 operating profit was affected by upfront costs for US product launch preparation and vendor diversification. Until these investments turn into sales, the pace of margin recovery may stay limited.

Low US share and reliance on overseas sales

With a US market share of about 0.2%, the company has room to grow, but it also faces intense competition and must secure distributors. Overseas sales were about 40% of revenue in 2023, so local regulation, contracts and exchange rates can directly affect results.

10

Risk factors

Product approvals and launch timing

The approval and launch timing for US products such as the uncemented knee implant will be confirmed as the company discloses it. Delays could slow the pace of US sales growth. R&D costs are expensed before approval, which weighs on short-term profit.

Earnings volatility and subsidiary effects

In 2024, operating profit fell 44.8% and the company posted a parent net loss. In Q1 2026, the company said consolidated operating profit declined from a year earlier because of subsidiary results. Quarterly earnings remain volatile.

Timing of shareholder returns

The company has mentioned dividends and share buybacks, but no specific amounts or timing have been disclosed. With the dividend yield effectively negligible, whether returns are actually paid is a point to watch. If they remain at the stated-intention stage, they are unlikely to act as a support factor.

11

What to watch next

  1. During Q4 2026

    Watch whether revenue and operating profit exceed Q3 levels during the seasonal peak, when surgeries and shipments typically rise. This tests whether the Q4 improvement the company expects shows up in actual flows.

  2. Late March 2027

    The 2026 annual report will formally disclose full-year and Q4 results. Operating cash flow, year-end debt ratio and changes in parent-owned equity can be checked alongside.

  3. Around May 2027

    Preliminary Q1 2027 results are expected. Last year's Q1 preliminary results were announced on May 8, and the key check is whether operating profit recovers from the KRW 886 million low in Q1 2026.

  4. Timing not disclosed

    When the company discloses approval and launch timing for US products such as the uncemented knee implant, the key check will be how the US share of revenue, about 20% now, changes.

12

Overall view

Corentec grew revenue from KRW 63.9 billion in 2022 to KRW 100.4 billion in 2025, and operating profit recovered to KRW 9.12 billion in 2025 after a loss-making 2024. In 2026 it sold its Woosung Pharma stake and reduced its debt ratio, tidying the balance sheet.

However, Q3 2026 operating profit fell 50.3% year on year, and the company returned to a parent-level net loss. The US now makes up about 20% of revenue, but its market share is about 0.2%, and upfront R&D spending may limit the pace of margin recovery.

The share price sits below book value, and profit over the last four quarters is concentrated in Q4 2025. The next checkpoints are the Q4 2026 seasonal peak, the full-year and Q4 results in the 2026 annual report, preliminary Q1 2027 results, and the timing of US product launches.

13

Sources

  1. Korea Exchange (KRX) — Prices · Market Cap · Volume
  2. FSS electronic disclosure system (DART) — Financial statements · Dividend filings
Show 14 more articles and sources
  1. medipana.com
  2. rapportian.com
  3. alphabiz.co.kr
  4. venturesquare.net
  5. corentec.com
  6. m.news.nate.com
  7. biotimes.co.kr
  8. hitnews.co.kr
  9. comp.wisereport.co.kr
  10. pharm.edaily.co.kr
  11. rapportian.com
  12. rapportian.com
  13. m.news.nate.com
  14. thevc.kr

Report written 2026-11-11 · Data as of 2026-11-10

This content is AI analysis of market data and web search results, provided for information only. It is not a solicitation or recommendation to invest. Investment decisions and their consequences are the investor's own responsibility. Data may be delayed or contain errors.

Other reports in this industry

View industry analysis